menu
    • menu
    [{"orgOrder":0,"company":"Centogene","sponsor":"Evotec","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Expanded Collaboration","leadProduct":"Induced pluripotent stem cell","moa":"","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Centogene","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Centogene \/ CENTOGENE","highestDevelopmentStatusID":"2","companyTruncated":"Centogene \/ CENTOGENE"},{"orgOrder":0,"company":"Centogene","sponsor":"Agios Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2021","type":"Partnership","leadProduct":"Mitapivat","moa":"Pyruvate kinase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Centogene","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Centogene \/ Agios","highestDevelopmentStatusID":"10","companyTruncated":"Centogene \/ Agios"},{"orgOrder":0,"company":"Centogene","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Neurology","graph2":"Discovery","graph3":"Centogene","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Centogene \/ Pfizer","highestDevelopmentStatusID":"2","companyTruncated":"Centogene \/ Pfizer"},{"orgOrder":0,"company":"Centogene","sponsor":"Agios Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2022","type":"Expanded Collaboration","leadProduct":"Mitapivat","moa":"PKR","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Centogene","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Centogene \/ Agios","highestDevelopmentStatusID":"10","companyTruncated":"Centogene \/ Agios"}]

    Find Clinical Drug Pipeline Developments & Deals by Centogene

    Menu

    Centogene

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Centogene

                            Germany arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Centogene

                            Germany arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mitapivat

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Sponsor : Agios Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Expanded Collaboration

                            DEALS_DEV arrow-down

                            Centogene and Agios Expand Partnership for Clinical Development of PYRUKYND (mitapivat) to Treat Children With...

                            Details : CENTOGENE’s proprietary CentoCard® dried blood spot technology provides easy logistics for central diagnostic testing. PYRUKYND (Mitapivat Sulfate), is a pyruvate kinase activator indicated for the treatment of hemolytic anemia in adults with pyruvate...

                            Brand Name : Pyrukynd

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            June 13, 2022

                            Lead Product(s) : Mitapivat

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Sponsor : Agios Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Expanded Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Centogene

                            Germany arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Centogene

                            Germany arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : Discovery

                            Sponsor : Pfizer Inc

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Centogene Announces Expansion of Data Access and Collaboration Agreement With Pfizer

                            Details : The initial agreement, which granted Pfizer access to data of interest from CENTOGENE’s Bio/Databank, was established in 2019 to advance the discovery and validation of novel genetic targets as candidates for the development of new therapies for rare d...

                            Brand Name : Undisclosed

                            Molecule Type : Undisclosed

                            Upfront Cash : Undisclosed

                            March 17, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Discovery

                            Sponsor : Pfizer Inc

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Centogene

                            Germany arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Centogene

                            Germany arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mitapivat

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Sponsor : Agios Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            CENTOGENE Expands Partnership With Agios to Generate Novel Insights Into Rare Blood Diseases

                            Details : Under the terms of the new agreement, CENTOGENE will provide genetic testing and clinical trial support for Agios’ three global, pivotal trials in thalassemia and sickle cell disease including AG-348 (Mitapivat).

                            Brand Name : AG-348

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            November 04, 2021

                            Lead Product(s) : Mitapivat

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Sponsor : Agios Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Centogene

                            Germany arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Centogene

                            Germany arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Induced pluripotent stem cell

                            Therapeutic Area : Genetic Disease

                            Study Phase : Discovery

                            Recipient : Evotec

                            Deal Size : Undisclosed

                            Deal Type : Expanded Collaboration

                            DEALS_DEV arrow-down

                            Evotec and Centogene Expand Collaboration into Gaucher Disease

                            Details : The collaboration brings together Evotec’s leading induced pluripotent stem cell platform and broad drug discovery and development capabilities with CENTOGENE’s global proprietary rare disease platform, including iPSC lines, to address the needs of t...

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            August 20, 2020

                            Lead Product(s) : Induced pluripotent stem cell

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Discovery

                            Recipient : Evotec

                            Deal Size : Undisclosed

                            Deal Type : Expanded Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth